GlassScriptPhysician profile
Roger P Friedenthal
NPI 1164521605
$2,860.33
in general payments reported to CMS, 2019-2025
26 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $758 · 2020: $247 · 2021: $251 · 2022: $338 · 2023: $477 · 2024: $327 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,265.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $660.00 | 2019 | |
| Abbvie INC. | $522.26 | 2020-2025 | |
| Acelrx Pharmaceuticals, INC. | $205.98 | 2020-2021 | |
| Janssen Biotech, INC. | $190.54 | 2021-2025 | Tremfya |
| Rti Surgical, INC | $165.01 | 2025 | |
| Sun Pharmaceutical Industries INC. | $147.86 | 2019-2025 | |
| Aroa Biosurgery Incorporated | $138.75 | 2024 | |
| Smith+Nephew, INC. | $122.78 | 2019-2025 | Collagenase Santyl |
| Incyte Corporation | $95.92 | 2022-2025 | Opzelura |
| Ucb, INC. | $68.74 | 2021-2022 | |
| Genzyme Corporation | $66.79 | 2024-2025 | |
| Lilly USA, LLC | $60.66 | 2022-2023 | Taltz, Olumiant |
| Allergan, INC. | $53.37 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41.48 | 2019-2021 | |
| Convatec INC. | $39.72 | 2022-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $33.99 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.15 | 2022 | |
| Leo Pharma INC. | $29.20 | 2020 | |
| Solventum Corporation | $28.93 | 2025 | Activ.A.C. |
| Vyne Pharmaceuticals INC. | $26.97 | 2020 | |
| Dermira, INC. | $26.40 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $24.24 | 2022 | |
| Molnlycke Health Care US, LLC | $23.65 | 2025 | Setopress, Mesalt, Mextra Superabsorbant |
| Organogenesis INC. | $21.44 | 2023 | Puraply |
| Novartis Pharmaceuticals Corporation | $20.56 | 2025 | |
| Dusa Pharmaceuticals, INC. | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Friedenthal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.